CCR1


Also found in: Acronyms.

CCR1

A gene on chromosome 3p21 that encodes a member of the beta chemokine receptor family, whose ligands include macrophage inflammatory protein 1 (MIP-1) alpha, regulated on activation normal T expressed and secreted protein (RANTES), monocyte chemoattractant protein 3 (MCP-3) and myeloid progenitor
inhibitory factor-1 (MPIF-1). The protein product transduces a signal by increasing intracellular calcium, and drives stem cell proliferation.
References in periodicals archive ?
Results from the CARAT-2 study have demonstrated clinical proof-of-concept of CCR1 inhibition in the treatment of RA," stated Thomas J.
Recent examples for true treatment failures--that means plausible rationale from pre-clinical investigations, but clear lack of efficacy under clinical conditions in the absence of major side effects--include the CCR1 antagonist BX-471, hydrolytic enzymes, anti-LFA-1 and anti-infective agents.
Other clinical programs include CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR inhibitor, in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development.
The initial cloning and characterization of CCR1 as well as the chemokine known as RANTES, one of the main ligands for CCR1, was accomplished by the founder of ChemoCentryx over twenty years ago," stated Paul-Peter Tak, M.
Forest will have exclusive rights to all CCR1 antagonists developed during that period and will take the lead in clinical development.
Other clinical programs include CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development.
Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in a Phase I clinical trial.
Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011.
Company's Novel CCR1 Antagonist Demonstrated Far Greater than 90% Receptor Coverage Throughout Day - Critical for Treatment of Disease
Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development.
Company's Novel CCR1 Antagonist Safely Provides Greater than 90% Receptor Coverage Throughout Day - Critical to the Treatment of Inflammatory Diseases
Additional clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus, CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis and CCX168, a C5aR antagonist, in Phase I clinical development.